Metropolis Healthcare LtdNSE: METROPOLIS
Open the Metropolis Healthcare Ltd page
Follow Metropolis Healthcare LtdFree account. Get a note when Metropolis Healthcare Ltd files.
Q1 FY27 earnings call · August 05, 2026

Metropolis Healthcare Ltd Q1 FY27 Earnings Call: Margins Expand 210 bps, Targets 500 Net Centers

Cofacto ResearchPublished August 05, 20265 min read
Quick summary

Metropolis Healthcare Ltd held its Q1 FY27 earnings call on August 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Volume-Led Beat; Margins Expand 210 bps

  • Q1 FY 2026-2027 revenue of Rs.2,450 Cr — grew 17% YoY, driven by 10% patient volume growth and 11% test volume growth; no price increases taken in the period.
  • EBITDA of Rs.113 Cr — up 27% YoY, with margin expanding 210 bps to 25.2%, exceeding the FY 2026-2027 guidance of 100-150 bps expansion.
  • PAT of Rs.57 Cr — grew 26% YoY, with PAT margin improving 90 bps to 12.6%.
  • B2C revenue grew 18% — and B2B revenue grew 15% in Q1 FY 2026-2027; wellness (True Health) grew 22% and specialty grew 17%.
  • Q1 revenue outperformed the full-year guidance of 14-15%, which management attributed to a combination of execution in under-penetrated markets and seasonal momentum, though it noted difficulty in fully dissecting the cause.

FY 2026-2027 Revenue Guidance Reaffirmed; Margin Trajectory Intact

  • Revenue growth guidance of 14-15% for FY 2026-2027 — reiterated by management, driven by 9-10% patient volume growth and 5-6% product mix improvement; guidance held despite a strong Q1 beat.
  • EBITDA margin expansion of 100-150 bps for FY 2026-2027 — guided by management, supported by productivity gains and operating leverage; medium-term target of 27-28% over FY 2026-2027 and FY 2027-2028.
  • No price hike taken in FY 2026-2027 — management chose to pass on the GST benefit to consumers; a potential price increase is implied for FY 2027-2028 to pass on cost inflation.
  • Capex guided at ~Rs.65 Cr for FY 2026-2027 — consistent with the FY 2025-2026 spend of Rs.65 Cr, including acquired entities.
  • Management cited climate change making weather patterns unpredictable, which heavily influences disease testing demand, as a difficulty in forecasting.

500 Net Centers Targeted; Tier 2/3 Push Continues

  • 300 gross centers added in Q1 FY 2026-2027 — offset by an equal number of closures from a rationalization exercise in tier 2/3 towns, resulting in a flat net count; net addition target of 500 centers for the full fiscal year.
  • Net addition target of 400-500 centers in Tier 2/3 towns for FY 2026-2027 — with 200-250 new centers per quarter expected to drive volume growth.
  • Center-to-laboratory ratio improved to 1:21 — in Q1 FY 2026-2027, with a target of 1:30 by end of FY 2026-2027; management sees no further major lab rationalization in FY 2026-2027.
  • North India contributes 18% of revenue — up from single digits pre-acquisition, growing 19% YoY in Q1 FY 2026-2027, making it the fastest-growing region.
  • Network rationalization is an infrequent exercise (once every 12-18 months) and is not expected to continue every quarter; recent closures had no revenue impact.

Wellness and Specialty Drive Mix; True Health Margins In-Line

  • Specialty portfolio at 40% of Q1 FY 2026-2027 revenue — growing 17% YoY; management targets increasing contribution to 45% over time, supported by a test menu of >2,200 tests.
  • Wellness (True Health) grew 22% in Q1 FY 2026-2027 — now 18% of revenue; management introduced "True Health Mind & Body," a screening initiative combining blood tests, basic radiology, and cognitive assessments, though no specific revenue targets were provided.
  • True Health's average ticket size is Rs.2,500 — and its margins are already in line with the company's overall margins for FY 2026-2027.
  • Realisation growth of 5-6% in Q1 FY 2026-2027 — entirely driven by mix shift toward higher-value wellness and specialty tests, with no price increase taken.
  • Wellness traction is currently concentrated in tier 1/2 cities but is gaining momentum in deeper tier 2/3 towns, following a sequential pattern: routine, semi-specialty, specialty, then wellness.

Core Diagnostics Margin Target of 25% in 3-4 Years; Bolt-Ons in View

  • Core Diagnostics reported high single-digit margins in Q1 FY 2026-2027 — management reiterated its target to bring Core's margins to 25% within 3-4 years of the acquisition (by approximately FY 2028-2029).
  • Core's FY 2026-2027 expected EBITDA implies an effective acquisition multiple of ~10x EBITDA — management stated both Core and True Health will be accretive to EBITDA growth over the next few years.
  • Management is open to bolt-on acquisitions — targeting strong consumer brands with ethical practices, good science, positive unit economics, and disciplined valuation; also open to larger EPS-accretive deals if the right value can be found and turned around.
  • Acquisitions of Dr. Dangs (Dehradun) and Scientifica (Agra) completed — towards the end of Q1 FY 2026-2027, with numbers now consolidated.
  • GLP-1 impact on diagnostics is still early days with potential to play out over a longer time frame; tests required for pre-GLP-1 prescriptions are common and difficult to isolate as specific to GLP-1 trends for Q1 FY 2026-2027.

Unorganized-to-Organized Shift Slow; CGHS Contribution Small

  • Shift from unorganized to organized players described as "slow and steady" — management noted anecdotally that volume growth at smaller labs is slower, with no catalyst for a sudden marked change (e.g., from 10-15% organized to 30%).
  • Only 10% of India's ~3 lakh labs run by MD pathologists — management noted that 90% are run by technicians, influencing the type of tests outsourced to organized players.
  • CGHS revenue is ~1% of total business — management confirmed the recent CGHS price revision provides a benefit on this small base, but the impact is not material compared to peers.
  • B2B competition described as normal intensity — management noted many entrants reach Rs.50-75 Cr in annual revenue but fail to scale profitably.
  • Management cited "government targeting 100% insurance penetration by 2047" as a long-term TAM driver, but noted the pace of organized shift remains gradual.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.